Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure

Heart

Volumn 92, Issue 5, 2006, Pages 625-630

  Kasama, S ^a   Toyama, T ^a   Hatori, T ^a   Sumino, H ^a   Kumakura, H ^b   Takayama, Y ^b   Ichikawa, S ^b   Suzuki, T ^a   Kurabayashi, M ^a  

^a GUNMA UNIVERSITY   (Japan)

^b Cardiovasc Hosp of Central Japan   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; DIGITALIS; ENALAPRIL; FUROSEMIDE; ISOSORBIDE MONONITRATE; LOOP DIURETIC AGENT; SPIRONOLACTONE; VALSARTAN; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE VOLUME; HEART NERVE; HUMAN; MALE; MEDIASTINUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCINTIGRAPHY; SYMPATHETIC NERVE; SYMPTOM;

3-IODOBENZYLGUANIDINE; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ENALAPRIL; FEMALE; HEART; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MEDIASTINUM; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; OBSERVER VARIATION; RADIOPHARMACEUTICALS; SYMPATHETIC NERVOUS SYSTEM; TETRAZOLES; VALINE;

EID: 33646269946     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2005.062463     Document Type: Article

References (40)

1. Henderson EB, Kahn JK, Corbett JR, et al. Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation 1988;78:1192-9.
2. Ogita H, Shimonagata T, Fukunami M, et al. Prognostic significance of cardiac (123)I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study. Heart 2001;86:656-60.
3. Merlet P, Valette H, Dubois-Rande JL, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992;33:471-7.
4. Yamazaki J, Muto H, Kabano T, et al. Evaluation of beta-blocker therapy in patients with dilated cardiomyopathy: clinical meaning of iodine 123-metaiodobenzylguanidine myocardial single-photon emission computed tomography. Am Heart J 2001;141:645-52.
5. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195-203.
6. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997;96:509-16.
7. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling - concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an international forum on cardiac remodeling. J Am Coll Cardiol 2000;35:569-82.
8. Harrap SB, Dominiczak AF, Fraser R, et al. Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults. Circulation 1996;93:1148-54.
9. Kasama S, Toyama T, Kumakura H, et al. Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. J Nucl Med 2002;43:1279-85.
10. Kasama S, Toyama T, Kumakura H, et al. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 2003;41:574-81.
11. Kasama S, Toyama T, Kumakura H, et al. Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure. J Nucl Med 2003;44:884-90.
12. Kasama S, Toyama T, Kumakura H, et al. Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity in patients with decompensated congestive heart failure. J Nucl Med 2004;45:1108-13.
13. Kasama S, Toyama T, Kumakura H, et al. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. J Am Coll Cardiol 2005;45:661-7.
14. Kasama S, Toyama T, Kumakura H, et al. Effects of perindopril on cardiac sympathetic nerve activity in patients with congestive heart failure: comparison with enalapril. Eur J Nucl Med Mol Imaging 2005;32:964-71.
15. Somsen GA, van Vlies B, de Milliano PA, et al. Increased myocardial [123I]-metaiodobenzylguanidine uptake after enalapril treatment in patients with chronic heart failure. Heart 1996,76:218-22.
16. Baruch L, Anand I, Cohen IS, et al. Vasodilator Heart Failure Trial (V-HeFT) Study Group. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Circulation 1999;99:2658-64.
17. De Tommasi E, Iacoviello M, Romito R, et al. Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure. Am Heart J 2003;146:E17.
18. Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
19. Kasama S, Toyama T, Hoshizaki H, et al. Dobutamine gated blood pool scintigraphy predicts the improvement of cardiac sympathetic nerve activity, cardiac function, and symptoms after treatment in patients with dilated cardiomyopathy. Chest 2002;122:542-8.
20. Kasama S, Toyama T, Kumakura H, et al. Effects of nicorandil on cardiac sympathetic nerve activity after reperfusion therapy in patients with first anterior acute myocardial infarction. Eur J Nucl Med Mol Imaging 2005;32:322-8.
21. Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002;105:539-42.
22. Kasama S, Toyama T, Kumakura H, et al. Dobutamine stress 99mTc-tetrofosmin quantitative gated SPECT predicts improvement of cardiac function after carvedilol treatment in patients with dilated cardiomyopathy. J Nucl Med 2004;45:1878-84.
23. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative north scandinavian enalapril survival study (CONSENSUS). N Engl J Med 1987;316:1429-35.
24. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
25. Curtiss C, Cohn JN, Vrobel T, et al. Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation 1978;58:763-70.
26. Urata H, Healy B, Stewart RW, et al. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990;66:883-90.
27. Balcells E, Meng QC, Johnson WH Jr, et al. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol 1997;273:H1769-74.
28. Bumpus FM, Catt KJ, Chiu AT, et al. Nomenclature for angiotensin receptors: a report of the Nomenclature Committee of the Council for High Blood Pressure Research. Hypertension 1991;17:720-1.
29. Leri A, Liu Y, Li B, et al. Up-regulation of AT(1) and AT(2) receptors in postinfarcted hypertrophied myocytes and stretch-mediated apoptotic cell death. Am J Pathol 2000;156:1663-72.
30. Francis GS, Cohn JN. Heart failure: mechanisms of cardiac and vascular dysfunction and the rationale for pharmacologic intervention. FASEB J 1990;4:3068-75.
31. Patten RD, Udelson JE, Konstam MA. Ventricular remodeling and its prevention in the treatment of heart failure. Curr Opin Cardiol 1998;13:162-7.
32. Kohno M, Horio T, Yokokawa K, et al. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med 1992;92:29-34.
33. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30.
34. Latini R, Masson S, Anand I, et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004;25:292-9.
35. Hughes J, Roth RH. Evidence that angiotensin enhances transmitter release during sympathetic nerve stimulation. Br J Pharmacol 1971;41:239-55.
36. Antonaccio MJ, Kerwin L. Evidence for prejunctional inhibition of norepinephrine release by captopril in spontaneously hypertensive rats, Eur J Pharmacol 1980;68:209-12.
37. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999;100:1056-64.
38. Sakata K, Shirotani M, Yoshida H, et al. Comparison of effects of enalapril and nitrendipine on cardiac sympathetic nervous system in essential hypertension. J Am Coll Cardiol 1998;32:438-43.
39. Kohno M, Horio T, Yokokawa K, et al. Brain natriuretic peptide as a marker for hypertensive left ventricular hypertrophy: changes during 1-year antihypertensive therapy with angiotensin-converting enzyme inhibitor. Am J Med 1995;98:257-65.
40. Shimizu T, Okamoto H, Chiba S, et al. Long-term combined therapy with an angiotensin type I receptor blocker and an angiotensin converting enzyme inhibitor prolongs survival in dilated cardiomyopathy. Jpn Heart J 2002;43:531-43.